



Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01600-US	SERIAL NO.: 10/673,888
INFORMATION DISCLOSURE STATEMENT FOR PATENT (Use several sheets if necessary)		APPLICANT: Evans <i>et al.</i>	
		FILING DATE: September 29, 2003	GROUP: TBA

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
RI	AA	5,719,148	Feb. 17, 1998	Bishop <i>et al.</i>	514	228.2	Mar. 24, 1995
RI	AB	5,874,442	Feb. 23, 1999	Doll <i>et al.</i>	514	290	Dec. 12, 1996

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
RI	AC	WO95/10516	April 20, 1995	WIPO	C07D	401/04		X
	AD							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RI	AE	Liu, <i>et al.</i> , (1998) "Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice" Cancer Res. 58:4974-4956;						
	AF	Njoroge, <i>et al.</i> , (1998) "Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity" J. Med. Chem. 41:1561-1567;						
	AG	Nagasu, <i>et al.</i> , (1995) "Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956" Cancer Res. 55:5310-5314						
	AH	Aklilu, <i>et al.</i> , (1997) "Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy" Cancer Res. 57:4517-4522						
	AI	Moseley, <i>et al.</i> , (1987) "Parathyroid hormone-related protein purified from a human lung cancer cell line." Proc. Natl. Acad. Sci. USA 84:5048-5052						
	AJ	Stewart, <i>et al.</i> , (1987) "N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: identification of parathyroid hormone-like and parathyroid hormone-unlike domains" Biochem. Biophys. Res. Comm. 146:672-678						
	AK	Stewler, <i>et al.</i> , (1987) "Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone." J. Clin. Invest. 80:1803-1807						
	AL	Rabbani, <i>et al.</i> , (1986) "Purification of peptides with parathyroid hormone-like bioactivity from human and rat malignancies associated with hypercalcemia." Endocrinology 118:1200-1210						
	AM	Li, <i>et al.</i> , (1994) "Growth factor-like properties of parathyroid hormone-related peptide in transfected rodent cell line" Cancer Res. 53:2980-2986						

EXAMINER /Roy Issac/ (09/18/2006)	DATE CONSIDERED 09/18/2006
--------------------------------------	-------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FEB 17 2004

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
OC01600-USSERIAL NO.:
10/673,888INFORMATION DISCLOSURE STATEMENT
FOR PATENT*(Use several sheets if necessary)*APPLICANT:
Evans *et al.*FILING DATE:
September 29, 2003GROUP:
TBA

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
RI	AC	WO 97/23478	July 3, 1997	WIPO	C07D	401/04		X
	AD							

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

RI	AE	International Search Report for International Application No. PCT/US03/30670						
RI	AF	Ayrat-Kaloustian <i>et al.</i> , "Protein Farnesyltransferase Inhibitors" Curr. Med. Chem. 9:1003-1032 (2002)						
	AG							
	AH							
	AI							
	AJ							
	AK							
	AL							
	AM							

EXAMINER
/Roy Issac/ (09/18/2006)DATE CONSIDERED
09/18/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.